216 related articles for article (PubMed ID: 36759424)
1. Nitroso Impurities in Drug Products: An Overview of Risk Assessment, Regulatory Milieu, and Control Strategy.
Charoo NA; Dharani S; Khan MA; Rahman Z
AAPS PharmSciTech; 2023 Feb; 24(2):60. PubMed ID: 36759424
[TBL] [Abstract][Full Text] [Related]
2. A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products.
Boetzel R; Schlingemann J; Hickert S; Korn C; Kocks G; Luck B; Blom G; Harrison M; François M; Allain L; Wu Y; Bousraf Y
J Pharm Sci; 2023 Jun; 112(6):1615-1624. PubMed ID: 35500671
[TBL] [Abstract][Full Text] [Related]
3. Modeling the Impact of Excipients Selection on Nitrosamine Formation towards Risk Mitigation.
Berardi A; Jaspers M; Dickhoff BHJ
Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631229
[TBL] [Abstract][Full Text] [Related]
4. Practical and Science-Based Strategy for Establishing Acceptable Intakes for Drug Product
Dobo KL; Kenyon MO; Dirat O; Engel M; Fleetwood A; Martin M; Mattano S; Musso A; McWilliams JC; Papanikolaou A; Parris P; Whritenour J; Yu S; Kalgutkar AS
Chem Res Toxicol; 2022 Mar; 35(3):475-489. PubMed ID: 35212515
[TBL] [Abstract][Full Text] [Related]
5. A comprehensive review of sources of nitrosamine contamination of pharmaceutical substances and products.
Akkaraju H; Tatia R; Mane SS; Khade AB; Dengale SJ
Regul Toxicol Pharmacol; 2023 Mar; 139():105355. PubMed ID: 36792049
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous determination of low molecular weight nitrosamines in pharmaceutical products by fast gas chromatography mass spectrometry.
Kalauz A; Tiringer KV; Horváth V; Kapui I
J Chromatogr A; 2023 Oct; 1708():464323. PubMed ID: 37696123
[TBL] [Abstract][Full Text] [Related]
7. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).
Kruhlak NL; Schmidt M; Froetschl R; Graber S; Haas B; Horne I; Horne S; King ST; Koval IA; Kumaran G; Langenkamp A; McGovern TJ; Peryea T; Sanh A; Siqueira Ferreira A; van Aerts L; Vespa A; Whomsley R
Regul Toxicol Pharmacol; 2024 Jun; 150():105640. PubMed ID: 38754805
[TBL] [Abstract][Full Text] [Related]
8. Regulatory Experiences with Root Causes and Risk Factors for Nitrosamine Impurities in Pharmaceuticals.
Horne S; Vera MD; Nagavelli LR; Sayeed VA; Heckman L; Johnson D; Berger D; Yip YY; Krahn CL; Sizukusa LO; Rocha NFM; Bream RN; Ludwig J; Keire DA; Condran G
J Pharm Sci; 2023 May; 112(5):1166-1182. PubMed ID: 36599405
[TBL] [Abstract][Full Text] [Related]
9. N-Nitrosamine Formation in Pharmaceutical Solid Drug Products: Experimental Observations.
Moser J; Ashworth IW; Harris L; Hillier MC; Nanda KK; Scrivens G
J Pharm Sci; 2023 May; 112(5):1255-1267. PubMed ID: 36736774
[TBL] [Abstract][Full Text] [Related]
10. METASTATIC NODULAR MELANOMA DEVELOPING ON NEVUS SPILUS DURING INTAKE OF BETA BLOCKERS (BISOPROLOL/NEBIVOLOL) AND ACE INHIBITORS (PERINDOPRIL). POTENTIAL LINKS TО THE DRUG RELATED NITROSOGENESIS/CARCINOGENESIS, DUNNING-KRUGER EFFECT AND GENETIC WEAPONS OF THE NEW GENERATION.
Tchernev G
Georgian Med News; 2023 Oct; (343):172-178. PubMed ID: 38096536
[TBL] [Abstract][Full Text] [Related]
11. Nitrosated Active Pharmaceutical Ingredients - Lessons Learned?
Holzgrabe U
J Pharm Sci; 2023 May; 112(5):1210-1215. PubMed ID: 36720391
[TBL] [Abstract][Full Text] [Related]
12. Trace Aldehydes in Solid Oral Dosage Forms as Catalysts for Nitrosating Secondary Amines.
Harmon P
J Pharm Sci; 2023 May; 112(5):1216-1219. PubMed ID: 36336102
[TBL] [Abstract][Full Text] [Related]
13. Nitrosamines crisis in pharmaceuticals - Insights on toxicological implications, root causes and risk assessment: A systematic review.
Vikram HPR; Kumar TP; Kumar G; Beeraka NM; Deka R; Suhail SM; Jat S; Bannimath N; Padmanabhan G; Chandan RS; Kumar P; Gurupadayya B
J Pharm Anal; 2024 May; 14(5):100919. PubMed ID: 38799236
[TBL] [Abstract][Full Text] [Related]
14. Nitrosamine Impurities in Pharmaceuticals: An Empirical Review of their Detection, Mechanisms, and Regulatory Approaches.
Bhirud D; Agrawal G; Shah H; Patel A; Palkar MB; Bhattacharya S; Prajapati BG
Curr Top Med Chem; 2024; 24(6):503-522. PubMed ID: 38321910
[TBL] [Abstract][Full Text] [Related]
15. Nitrosamine Contamination in Pharmaceuticals: Threat, Impact, and Control.
Tuesuwan B; Vongsutilers V
J Pharm Sci; 2021 Sep; 110(9):3118-3128. PubMed ID: 33989680
[TBL] [Abstract][Full Text] [Related]
16. Critical Analysis of Drug Product Recalls due to Nitrosamine Impurities.
Bharate SS
J Med Chem; 2021 Mar; 64(6):2923-2936. PubMed ID: 33706513
[TBL] [Abstract][Full Text] [Related]
17. Analytical Method Capable of Quantifying Eight Nitrosamine Impurities from Five Different Commercially Available Metformin Formulations with Glipizide, Glibenclamide, Gliclazide, Evogliptin, and Glimepiride by Ultra High Performance Liquid Chromatography Tripple Quadrupole Mass Spectrometry.
Solanki R; Wadhwana P; Patel R; Gayakvad B; Kothari C; Patel C
J Pharm Sci; 2023 May; 112(5):1268-1276. PubMed ID: 36822274
[TBL] [Abstract][Full Text] [Related]
18. NITROSOGENESIS OF SKIN (HUMAN) CANCER- THE HIDDEN TRUTH OF A NEVERENDING STORY: NITROSAMINE CONTAMINATION IN OLMESARTAN, VALSARTAN AND HCT AS MAIN RISK FACTOR FOR THE DEVELOPMENT OF KERATINOCYTE CANCER.
Tchernev G; Kordeva S
Georgian Med News; 2023 Apr; (337):63-67. PubMed ID: 37354675
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous Estimation of Six Nitrosamine Impurities in Valsartan Using Liquid Chromatographic Method.
Bodiwala KB; Panchal BG; Savale SS; Dave JB; Sureja DK; Dhameliya TM; Chhabria MT
J AOAC Int; 2022 Feb; 105(1):1-10. PubMed ID: 34338773
[TBL] [Abstract][Full Text] [Related]
20. Regulatory Updates and Analytical Methodologies for Nitrosamine Impurities Detection in Sartans, Ranitidine, Nizatidine, and Metformin along with Sample Preparation Techniques.
Shaik KM; Sarmah B; Wadekar GS; Kumar P
Crit Rev Anal Chem; 2022; 52(1):53-71. PubMed ID: 32691615
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
